ARISTOTLE UNIVERSITY OF THESSALONIKI

Cabazitaxel demonstrated efficacy in mCRPC patients with bone metastases, including those with HRR mutations. Reactive hematopoiesis correlated with improved survival, suggesting bone biomarkers as predictors of cabazitaxel efficacy.